Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
Delayed Quote. Delayed Nasdaq - 06/18 04:00:00 pm
68.2 USD   +1.64%
06/17GILEAD SCIENCES : A new era for Gilead
AQ
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
DJ
06/13GILEAD SCIENCES : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : , HHS chief announce donation of HIV prevention drug Truvada

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2019 | 11:08am EDT

Health and Human Services Secretary Alex M. Azar this week announced a deal for drugmaker Gilead Sciences to donate billions of dollars in HIV drugs to help prevent spread of the disease.

The pharmaceutical company on Thursday agreed to donate pre-exposure prophylaxis medication Truvada to roughly 200,000 people living in states and counties hardest hit by HIV. Those receiving the drug will be uninsured and at risk for HIV, HHS said.

Truvada has been shown to reduce the risk of HIV transmission by 97 percent.

The drug has a list price of $20,000 per patient each year, making the donation worth billions of dollars, HHS said.

"Securing this commitment is a major step in the Trump Administration's efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030," Alex Azar, Health and Human Services secretary, said in a news release. "Under President Trump's leadership, HHS worked with Gilead to secure preventative medication for individuals who might otherwise not be able to access or afford this important treatment."

The deal between Gilead and HHS will stand through at least Dec. 31, 2025, but could extend to Dec. 31, 2030.

Gilead has agreed to donate Truvada until the company's next-generation preventative HIV drug, Descovy, is available. The company will then donate Descovy as a part of the 11-year deal, or until the drug's generic version hits the market.

The announcement from HHS is part of Trump's plan to target 48 counties throughout the United States to eliminate HIV transmission over the next decade.

"The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication," Azar said. "This agreement will help close that gap substantially and deliver on President Trump's promise to end the HIV epidemic in America."

Copyright 2019 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
06/17GILEAD SCIENCES : A new era for Gilead
AQ
06/14GILEAD SCIENCES : A cure for HIV? Gilead VP in Israel for Pride Parade says one ..
AQ
06/14GILEAD SCIENCES : AbCellera Announces Therapeutic Antibody Discovery Collaborati..
AQ
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
DJ
06/13GILEAD SCIENCES : Ex-dividend day for
FA
06/11GILEAD SCIENCES : Statement on U.S. Preventive Services Task Force 'A' Recommend..
PU
06/04GILEAD SCIENCES : Kite Announces New Yescarta Data from ZUMA-1
AQ
06/03GILEAD SCIENCES : Company - Kite and Humanigen Announce Clinical Collaboration t..
AQ
06/03GILEAD SCIENCES : Kite Announces New Yescarta® Data From ZUMA-1
BU
06/03GILEAD SCIENCES : Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Ad..
AQ
More news
Financials ($)
Sales 2019 22 048 M
EBIT 2019 11 439 M
Net income 2019 6 954 M
Debt 2019 5 969 M
Yield 2019 3,87%
P/E ratio 2019 12,02
P/E ratio 2020 11,86
EV / Sales 2019 4,04x
EV / Sales 2020 3,66x
Capitalization 83 096 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523
NEUROCRINE BIOSCIENCES, INC.20.46%7 500